Literature DB >> 22996319

Alloantigen-specific regulatory T cells prevent experimental chronic graft-versus-host disease by simultaneous control of allo- and autoreactivity.

Pervinder Sagoo1, Kulachelvy Ratnasothy, Yuen Tsang, Linda D Barber, Alistair Noble, Robert I Lechler, Giovanna Lombardi.   

Abstract

Chronic graft-versus-host disease (cGVHD) is characterised by a complex etiology of both alloimmune- and autoimmune-mediated disease progression and pathology, and is consequently difficult to control. The therapeutic potential of regulatory T (Treg) cells for cGVHD is currently being investigated; however, the relative ability of Treg cells with defined antigen specificities for auto- and alloantigen to prevent disease has not been previously examined. In this study, we show that donor-derived Treg-cell lines generated with self-MHC H-2(b) specificity or specificity for BALB/c H-2(d) alloantigen presented via the direct or indirect pathways are able to mediate an equal protection against cGVHD immune pathology in a disease model associated with recipient B-cell-driven humoral autoimmunity and glomerulonephritis. Mechanistically, autospecific Treg cells prevented disease induction by blocking donor T-cell engraftment whereas allospecific Treg cells permitted long-term engraftment of donor T cells. Donor T cells, while unresponsive to auto- and recipient alloantigens, retained the capacity to respond to third party alloantigens on ex vivo stimulation. These findings indicate that allospecific Treg cells may therefore be more clinically relevant as a cell therapy for cGVHD in the context of haplo-identical hematopoietic transplantation, as they allow persistence of donor T cells capable of responding to foreign antigens whilst preventing cGVHD-mediated autoimmunity.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996319     DOI: 10.1002/eji.201242770

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity.

Authors:  Kangkang Lv; Bo Hu; Mingzhu Xu; Li Wan; Ziqi Jin; Mimi Xu; Yuanyuan Du; Kunpeng Ma; Quansheng Lv; Yang Xu; Lei Lei; Huanle Gong; Haiyan Liu; Depei Wu; Yuejun Liu
Journal:  Exp Hematol Oncol       Date:  2022-06-02

2.  The role of regulatory T cells in the biology of graft versus host disease.

Authors:  Amy J Beres; William R Drobyski
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

3.  Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation.

Authors:  S Landman; V L de Oliveira; M Peppelman; E Fasse; E van Rijssen; S C Bauland; P van Erp; I Joosten; H J P M Koenen
Journal:  J Immunol Res       Date:  2020-05-14       Impact factor: 4.818

4.  In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice.

Authors:  Gaëlle H Martin; Sylvie Grégoire; Dan A Landau; Caroline Pilon; Yenkel Grinberg-Bleyer; Frédéric Charlotte; Jean-Pierre Mège; Lucienne Chatenoud; Benoît L Salomon; José L Cohen
Journal:  Eur J Immunol       Date:  2013-07-09       Impact factor: 5.532

Review 5.  Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.

Authors:  Alaa Alzhrani; Matthew Bottomley; Kathryn Wood; Joanna Hester; Fadi Issa
Journal:  Cell Immunol       Date:  2020-09-09       Impact factor: 4.868

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.